Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
September 10, 2024
Jasper Therapeutics to Present at Upcoming September Investor Conferences
September 4, 2024
Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
August 13, 2024
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
June 19, 2024
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
June 14, 2024
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
May 30, 2024
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference
May 29, 2024
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
May 14, 2024
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
May 13, 2024
Displaying 1 - 10 of 24